Aldeyra Therapeutics, Inc. is a biotechnology company focused on the discovery and commercialization of therapeutic agents for ocular and systemic immune-mediated disorders. The firm's primary investigational compound is reproxalap, a reactive aldehyde species (RASP) modulator, currently in Phase III clinical trials for addressing dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing ADX-629, an innovative, first-in-class RASP modulator designed for oral administration, which is undergoing Phase II studies for conditions such as psoriasis, asthma, and COVID-19.